Assessing Ocular Surface Changes After Changing Glaucoma Medications

University of Colorado, Denver22 enrolled

Overview

Hypothesis: Changing to Travatan Z therapy increases the tear film break up time of subjects on Xalatan therapy presenting with ocular surface disease.

Patients who have been taking Xalatan monotherapy to treat their glaucoma and presenting with ocular surface disease will be advised to switch their medication to Travatan Z. Test results will be recorded at the day that the medication was changed and at follow-up to determine if there is a measurable change in tear film break up, corneal staining and in the Ocular Surface Disease Index.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Glaucoma Monotherapy With Xalatan From 1 to 18 Months Ocular Surface Disease

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * on Xalatan monotherapy from 1 to 18 months * 18 years of age or older * has been diagnosed with ocular surface disease Exclusion Criteria: * special populations such as children, pregnant females, prisoners, etc.

Locations (1)

Rocky Mountain Lions Eye Institute

Aurora, Colorado, United States

Outcomes

Primary Outcomes

Change in Signs and Symptoms of Ocular Surface Disease

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.